Hepatocellular carcinoma‐infiltrating γδ T cells are functionally defected and allogenic Vδ2+ γδ T cell can be a promising complement

Abstract In hepatocellular carcinoma (HCC), γδ T cells participate in mediating the anti‐tumour response and are linked with a positive prognosis. However, these cells can become pro‐tumoural in the tumour microenvironment (TME). We aimed to decipher the immune landscape and functional states of HCC‐infiltrating γδ T cells to provide fundamental evidence for the adoptive transfer of allogeneic Vδ2+ γδ T cells in HCC immunotherapy. We performed single‐cell RNA sequencing (scRNA‐seq) on γδ T cells derived from HCC tumours and healthy donor livers. Confocal microscopy, flow cytometry and a Luminex assay were applied to validate the scRNA‐seq findings. The γδ T cells in the HCC TME entered G2/M cell cycle arrest, and expressed cytotoxic molecules such as interferon‐gamma and granzyme B, but were functionally exhausted as indicated by upregulated gene and protein LAG3 expression. The γδ T cells in the HCC TME were dominated by the LAG3+Vδ1+ population, whereas the Vδ2+ γδ T population was greatly depleted. Moreover, glutamine metabolism of γδ T cells was markedly upregulated in the glutamine‐deficient TME. Both in vitro and in vivo experiments showed that glutamine deficiency upregulated LAG3 expression. Finally, our results indicated that ex vivo‐expanded Vδ2+ γδ T cells from healthy donor could complement the loss of T cell receptor clonality and effector functions of HCC‐derived γδ T cells. This work deciphered the dysfunctional signatures of HCC‐infiltrating γδ T cells in the HCC TME, providing scientific support for the use of allogeneic Vδ2+ γδ T cells in HCC cellular therapy.

[1]  Z. An,et al.  Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma , 2021, Journal for ImmunoTherapy of Cancer.

[2]  M. Gale,et al.  Single-cell transcriptomic analyses of T cells in chronic HCV-infected patients dominated by DAA-induced interferon signaling changes , 2021, PLoS pathogens.

[3]  P. Sham,et al.  Single-cell RNA sequencing shows the immunosuppressive landscape and tumor heterogeneity of HBV-associated hepatocellular carcinoma , 2021, Nature Communications.

[4]  B. Sangro,et al.  Advances in immunotherapy for hepatocellular carcinoma , 2021, Nature Reviews Gastroenterology & Hepatology.

[5]  Huanming Yang,et al.  Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma , 2020, Cell.

[6]  Y. Hu,et al.  Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer , 2020, Cellular & molecular immunology.

[7]  J. Powell,et al.  Metabolism of immune cells in cancer , 2020, Nature Reviews Cancer.

[8]  Zonghai Li,et al.  Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials , 2020, Clinical Cancer Research.

[9]  Jian Huang,et al.  Breast cancer-derived exosomes transmit lncRNA SNHG16 to induce CD73+γδ1 Treg cells , 2020, Signal Transduction and Targeted Therapy.

[10]  Lei Liu,et al.  Single-cell RNA sequencing reveals the heterogeneity of liver-resident immune cells in human , 2020, Cell Discovery.

[11]  M. Lima,et al.  Human Peripheral Blood Gamma Delta T Cells: Report on a Series of Healthy Caucasian Portuguese Adults and Comprehensive Review of the Literature , 2020, Cells.

[12]  E. Pamer,et al.  Impact of TCR Diversity on the Development of Transplanted or Chemically Induced Tumors , 2019, Cancer Immunology Research.

[13]  J. Powell,et al.  Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion , 2019, Science.

[14]  Xianwen Ren,et al.  Landscape and Dynamics of Single Immune Cells in Hepatocellular Carcinoma , 2019, Cell.

[15]  Li Ding,et al.  Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma , 2019, Cell.

[16]  L. Ysebaert,et al.  Single-cell RNA sequencing unveils the shared and the distinct cytotoxic hallmarks of human TCRVδ1 and TCRVδ2 γδ T lymphocytes , 2019, Proceedings of the National Academy of Sciences.

[17]  J. Ijzermans,et al.  GITR ligation enhances functionality of tumor‐infiltrating T cells in hepatocellular carcinoma , 2019, International journal of cancer.

[18]  Z. Yin,et al.  Allogenic Vγ9Vδ2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma , 2019, Journal of Immunotherapy for Cancer.

[19]  D. Venzon,et al.  The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma , 2019, Cancer Immunology, Immunotherapy.

[20]  G. Zhu,et al.  Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3 , 2019, Cell.

[21]  K. Vousden,et al.  A Role for p53 in the Adaptation to Glutamine Starvation through the Expression of SLC1A3 , 2018, Cell metabolism.

[22]  Gary D Bader,et al.  Single cell RNA sequencing of human liver reveals distinct intrahepatic macrophage populations , 2018, Nature Communications.

[23]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[24]  S. Potter,et al.  Single-cell RNA sequencing for the study of development, physiology and disease , 2018, Nature Reviews Nephrology.

[25]  J. Llovet,et al.  Molecular therapies and precision medicine for hepatocellular carcinoma , 2018, Nature Reviews Clinical Oncology.

[26]  Erik Sundström,et al.  RNA velocity of single cells , 2018, Nature.

[27]  Helge G. Roider,et al.  Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing , 2018, Nature Medicine.

[28]  G. Sireci,et al.  γδ T Cells and Tumor Microenvironment: From Immunosurveillance to Tumor Evasion , 2018, Front. Immunol..

[29]  I. Lyadova,et al.  Th1, Th17, and Th1Th17 Lymphocytes during Tuberculosis: Th1 Lymphocytes Predominate and Appear as Low-Differentiated CXCR3+CCR6+ Cells in the Blood and Highly Differentiated CXCR3+/−CCR6− Cells in the Lungs , 2018, The Journal of Immunology.

[30]  Boxi Kang,et al.  Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing , 2017, Cell.

[31]  Ming Zhou,et al.  Interplay between Immune Checkpoint Proteins and Cellular Metabolism. , 2017, Cancer research.

[32]  Ho Chul Kang,et al.  Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3 , 2016, Science.

[33]  Chi V. Dang,et al.  From Krebs to clinic: glutamine metabolism to cancer therapy , 2016, Nature Reviews Cancer.

[34]  V. Kuchroo,et al.  Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. , 2016, Immunity.

[35]  Linda V. Sinclair,et al.  Glucose and glutamine fuel protein O-GlcNAcylation to control T cell self-renewal and malignancy , 2016, Nature Immunology.

[36]  Charles H. Yoon,et al.  Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq , 2016, Science.

[37]  Ash A. Alizadeh,et al.  Abstract PR09: The prognostic landscape of genes and infiltrating immune cells across human cancers , 2015 .

[38]  E. Jaffee,et al.  Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells , 2015, Cancer Immunology Research.

[39]  Zhiyuan Hu,et al.  LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses. , 2014, Cancer research.

[40]  Jae-Hoon Chang,et al.  Inflammatory T cell responses rely on amino acid transporter ASCT2 facilitation of glutamine uptake and mTORC1 kinase activation. , 2014, Immunity.

[41]  S. Qiu,et al.  The functional impairment of HCC-infiltrating γδ T cells, partially mediated by regulatory T cells in a TGFβ- and IL-10-dependent manner. , 2013, Journal of hepatology.

[42]  M. Todaro,et al.  Differentiation, phenotype, and function of interleukin-17-producing human Vγ9Vδ2 T cells. , 2011, Blood.

[43]  M. Todaro,et al.  Differentiation, phenotype, and function ofinterleukin-17-producing human V{gamma}9V{delta}2 T cells , 2011 .

[44]  M. Tan,et al.  Impact of age, gender, and race on circulating γδ T cells. , 2010, Human immunology.

[45]  Helen Y Wang,et al.  Tumor-Infiltrating γδ T Cells Suppress T and Dendritic Cell Function via Mechanisms Controlled by a Unique Toll-like Receptor Signaling Pathway , 2007 .

[46]  H. Jomaa,et al.  Sex‐specific phenotypical and functional differences in peripheral human Vγ9/Vδ2 T cells , 2006 .

[47]  B. Rehermann,et al.  The liver as an immunological organ , 2006, Hepatology.

[48]  Tong Tong,et al.  GADD45-induced cell cycle G2-M arrest associates with altered subcellular distribution of cyclin B1 and is independent of p38 kinase activity , 2002, Oncogene.

[49]  Jean-Saville Cummings,et al.  Impact of age, gender and race on circulating gammadelta T cells , 2010 .

[50]  Helen Y Wang,et al.  Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. , 2007, Immunity.

[51]  H. Jomaa,et al.  Sex-specific phenotypical and functional differences in peripheral human Vgamma9/Vdelta2 T cells. , 2006, Journal of leukocyte biology.

[52]  D. Doherty,et al.  Resident human hepatic lymphocytes are phenotypically different from circulating lymphocytes. , 1998, Journal of hepatology.